(Q34143393)

31 July 2017

1 reference

title

The fluoroquinolone antibacterials: past, present and future perspectives (English)

1 reference

31 July 2017

Appelbaum PC

1

1 reference

PubMed ID

11185413

31 July 2017

Hunter PA

series ordinal

2

1 reference

31 July 2017

1 September 2000

1 reference

International Journal of Antimicrobial Agents

31 July 2017

1 reference

31 July 2017

16

1 reference

31 July 2017

5-15

1 reference

31 July 2017

1

1 reference

Comparative tolerability of the newer fluoroquinolone antibacterials

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Potential interactions of the extended-spectrum fluoroquinolones with the CNS.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

1,8-Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Structure-activity and structure-side-effect relationships for the quinolone antibacterials

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

The 4-quinolone antibiotics: past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Quinolones: structure-activity relationships and future predictions

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Structure-activity relationships in DNA gyrase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Comparative activity of the new fluoroquinolone Bay y3118 against 177 penicillin susceptible and resistant pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Pneumococcal resistance to antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

The comparative in-vitro activity of ofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Comparative activities of clinafloxacin against gram-positive and -negative bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

In vitro antibacterial activity of DU-6859a, a new fluoroquinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxa

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

The activity of ciprofloxacin and other 4-quinolones againstChlamydia trachomatis andMycoplasmas in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Susceptibility of Chlamydia trachomatis to trovafloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Improved antimicrobial activity of DU-6859a, a new fluoroquinolone, against quinolone-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates with alterations in GyrA and ParC proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Quinolone activity against anaerobes: microbiological aspects.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

Antimicrobial activity of LB20304, a fluoronaphthyridone, tested against anaerobic bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900192-8

7 January 2021

10.1016/S0924-8579(00)00192-8

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11185413